Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 4:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–15 of 15 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Armodafinil 250 mg Clear all
Completed Phase 2Phase 3 Interventional

Use of Armodafinil for Fatigue in Sarcoidosis

NCT00555347
View directory record Official record
Conditions
Sarcoidosis, Fatigue, Sleepiness
Interventions
Armodafinil, Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 26, 2015 · Synced Sep 22, 2026, 4:05 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Pharmacodynamic Profile of SPD489 in Healthy Adult Males Undergoing a Nocturnal Period of Acute Sleep Loss

NCT01096680
View directory record Official record
Conditions
Sleep Deprivation
Interventions
SPD489 20 mg, SPD489 50 mg, SPD489 70 mg, Armodafinil, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 40 Years · Male only
Enrollment
135 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 13, 2021 · Synced Sep 22, 2026, 4:05 AM EDT
Completed Phase 3 Interventional Results available

Extension Study of the Safety and Efficacy of Armodafinil in the Treatment of Patients With Excessive Sleepiness

NCT00228553
View directory record Official record
Conditions
Excessive Daytime Sleepiness, Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, Chronic Shift Work Sleep Disorder
Interventions
Armodafinil 100 to 250 mg/day
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 65 Years
Enrollment
743 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
74
States / cities
Birmingham, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 64 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2013 · Synced Sep 22, 2026, 4:05 AM EDT
Completed Phase 4 Interventional Results available

"Pilot Study of Armodafinil in Patients With Dementia With Lewy Bodies"

NCT01023672
View directory record Official record
Conditions
Dementia With Lewy Bodies
Interventions
Armodafinil
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
50 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 4, 2013 · Synced Sep 22, 2026, 4:05 AM EDT
Terminated Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Armodafinil as Treatment for Patients With Excessive Sleepiness Associated With Mild or Moderate Closed Traumatic Brain Injury

NCT00893789
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Armodafinil, Placebo
Drug · Other
Lead sponsor
Cephalon, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
68
States / cities
Birmingham, Alabama • Tucson, Arizona • Hot Springs, Arkansas + 53 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2021 · Synced Sep 22, 2026, 4:05 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess Patient Reported Outcomes With Armodafinil Treatment for Excessive Sleepiness in Adults With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome

NCT00228566
View directory record Official record
Conditions
Excessive Daytime Sleepiness, Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome (OSAHS)
Interventions
Armodafinil
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 65 Years
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
43
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Phoenix, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2013 · Synced Sep 22, 2026, 4:05 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Cross-over Study of Armodafinil Treatment of Daytime Sleepiness Associated With Treated Nocturia

NCT02151253
View directory record Official record
Conditions
Nocturia, Daytime Sleepiness
Interventions
Armodafinil, Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 90 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Sep 22, 2026, 4:05 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

PET Study Examining the Dopaminergic Activity of Armodafinil in Adults

NCT00592943
View directory record Official record
Conditions
Healthy
Interventions
armodafinil
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 35 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 12, 2013 · Synced Sep 22, 2026, 4:05 AM EDT
Terminated Phase 3 Interventional Results available

Study to Evaluate the Safety, Tolerability, and Efficacy of Armodafinil as Treatment for Patients With Excessive Sleepiness Associated With Mild or Moderate Closed Traumatic Brain Injury

NCT00983437
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Armodafinil
Drug
Lead sponsor
Cephalon, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
61
States / cities
Birmingham, Alabama • Tucson, Arizona • Hot Springs, Arkansas + 49 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2021 · Synced Sep 22, 2026, 4:05 AM EDT
Completed Phase 3 Interventional Results available

Study of the Efficacy and Multiple-Dose Plasma Concentration-Time Profiles of Armodafinil and PROVIGIL

NCT00236080
View directory record Official record
Conditions
Chronic Shift Work Sleep Disorder
Interventions
PROVIGIL 200 mg, Armodafinil 250 mg, Armodafinil 200 mg, Armodafinil 150 mg, Placebo
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 65 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
20
States / cities
Phoenix, Arizona • Tucson, Arizona • Hot Springs, Arkansas + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2013 · Synced Sep 22, 2026, 4:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Armodafinil on Simulated Driving

NCT02468856
View directory record Official record
Conditions
Healthy Volunteers
Interventions
armodafinil, Placebo (for armodafinil)
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 35 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 30, 2018 · Synced Sep 22, 2026, 4:05 AM EDT
Completed Phase 3 Interventional Results available

Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma

NCT01781468
View directory record Official record
Conditions
Fatigue
Interventions
armodafinil 150 mg, Placebo, armodafinil 250 mg
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
365
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 254 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2025 · Synced Sep 22, 2026, 4:05 AM EDT
Completed Phase 3 Interventional Results available

Armodafinil (CEP-10953) for Treatment of Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, or Chronic Shift Work Sleep Disorder

NCT00078312
View directory record Official record
Conditions
Narcolepsy, Sleep Apnea, Obstructive, Sleep Apnea Syndromes, Shift-Work Sleep Disorder
Interventions
CEP-10953 (Armodafinil)
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 65 Years
Enrollment
328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
41
States / cities
Peoria, Arizona • Phoenix, Arizona • Tucson, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2013 · Synced Sep 22, 2026, 4:05 AM EDT
Completed Phase 4 Interventional Results available

Effectiveness of Armodafinil for Treating Fatigue in Adults With HIV/AIDS

NCT00737204
View directory record Official record
Conditions
HIV Infections, Fatigue
Interventions
Armodafinil, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 11, 2014 · Synced Sep 22, 2026, 4:05 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of Armodafinil as Adjunctive Therapy in Adults With Schizophrenia

NCT00772005
View directory record Official record
Conditions
Schizophrenia
Interventions
armodafinil, placebo
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 65 Years
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
39
States / cities
Little Rock, Arkansas • Anaheim, California • Escondido, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2012 · Synced Sep 22, 2026, 4:05 AM EDT